SavedAdd your journal

Journals / Archives of Rheumatology / 2022 / Cilt: 37 - Sayı: 1

Biological treatment in resistant adult-onset Still’s disease: A single-center, retrospective cohort study

Muhammet ÇINAR
Seda ÇOLAK
Emre TEKGÖZ
Sedat YILMAZ
Maghrur MAMMADOV
Pages
11–18
Publication Date
2022-10-11
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

Due to the administration methods and the high costs of these drugs, however, tapering the treatment should be considered, after remission is achieved.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Objectives: The aim of this study was to assess the demographic and clinical characteristics of patients with adult-onset Still’s disease (AOSD) under biological treatment.
📊
Key Findings & Data:Patients and methods: This retrospective cohort study included a total of 19 AOSD patients (13 males, 6 females; median age: 37 years; range, 28 to 52 years) who received biological drugs due to refractory disease between January 2008 and January 2020.
💡
Conclusion & Impact:Due to the administration methods and the high costs of these drugs, however, tapering the treatment should be considered, after remission is achieved.
🔬Design:Research Article
📍Scope:2008 Verileri
⚙️Variables:Domain Parameters

Abstract

Objectives: The aim of this study was to assess the demographic and clinical characteristics of patients with adult-onset Still’s disease (AOSD) under biological treatment. Patients and methods: This retrospective cohort study included a total of 19 AOSD patients (13 males, 6 females; median age: 37 years; range, 28 to 52 years) who received biological drugs due to refractory disease between January 2008 and January 2020. The data of the patients were obtained from the patient files. The response to the treatment was evaluated based on clinical and laboratory assessments at third and sixth follow-up visits. Results: Interleukin (IL)-1 inhibitor was prescribed for 13 (68.4%) patients and IL-6 inhibitor prescribed for six (31.6%) patients. Seventeen (89.5%) patients experienced clinical remission. Conclusion: Biological drugs seem to be effective for AOSD patients who are resistant to conventional therapies. Due to the administration methods and the high costs of these drugs, however, tapering the treatment should be considered, after remission is achieved.

🔖

Cite This Article

ÇINAR, M., ÇOLAK, S., TEKGÖZ, E., YILMAZ, S., MAMMADOV, M. (2022). Biological treatment in resistant adult-onset Still’s disease: A single-center, retrospective cohort study. Archives of Rheumatology, Cilt: 37 - Sayı: 1, 11–18. https://ajindex.com/articles/447951

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (15)

  1. Giacomelli R, Ruscitti P, Shoenfeld Y. A comprehensive review on adult onset Still’s disease. J Autoimmun 2018;93:24-36
  2. Bywaters EG. Still's disease in the adult. Ann Rheum Dis 1971;30:121-33
  3. Sugiura T, Maeno N, Kawaguchi Y, Takei S, Imanaka H, Kawano Y, et al. A promoter haplotype of the interleukin-18 gene is associated with juvenile idiopathic arthritis in the Japanese population. Arthritis Res Ther 2006;8:R60
  4. Liu Y, Xia C, Chen J, Fan C, He J. Elevated circulating pro-inflammatory low-density granulocytes in adult-onset Still's disease. Rheumatology (Oxford) 2021;60:297-303
  5. Seco T, Cerqueira A, Costa A, Fernandes C, Cotter J. Adult-onset Still's disease: Typical presentation, delayed diagnosis. Cureus 2020;12:e8510
  6. Al-Homood IA. Biologic treatments for adultonset Still’s disease. Rheumatology (Oxford) 2014;53:32-8
  7. Yamaguchi M, Ohta A, Tsunematsu T, Kasukawa R, Mizushima Y, Kashiwagi H, et al. Preliminary criteria for classification of adult Still's disease. J Rheumatol 1992;19:424-30
  8. Pay S, Türkçapar N, Kalyoncu M, Simek I, Beyan E, Ertenli I, et al. A multicenter study of patients with adult-onset Still's disease compared with systemic juvenile idiopathic arthritis. Clin Rheumatol 2006;25:639-44
  9. Ruscitti P, Cipriani P, Liakouli V, Guggino G, Carubbi F, Berardicurti O, et al. Managing adult-onset Still's disease: The effectiveness of high-dosage of corticosteroids as first-line treatment in inducing the clinical remission. Results from an observational study. Medicine (Baltimore) 2019;98:e15123
  10. Gerfaud-Valentin M, Jamilloux Y, Iwaz J, Sève P. Adultonset Still's disease. Autoimmun Rev 2014;13:708-22
  11. Pascual V, Allantaz F, Arce E, Punaro M, Banchereau J. Role of interleukin-1 (IL-1) in the pathogenesis of systemic onset juvenile idiopathic arthritis and clinical response to IL-1 blockade. J Exp Med 2005;201:1479-86
  12. Chen DY, Lan JL, Lin FJ, Hsieh TY. Proinflammatory cytokine profiles in sera and pathological tissues of patients with active untreated adult onset Still's disease. J Rheumatol 2004;31:2189-98
  13. Wada T, Kanegane H, Ohta K, Katoh F, Imamura T, Nakazawa Y, et al. Sustained elevation of serum interleukin-18 and its association with hemophagocytic lymphohistiocytosis in XIAP deficiency. Cytokine 2014;65:74-8
  14. Novick D, Kim S, Kaplanski G, Dinarello CA. Interleukin-18, more than a Th1 cytokine. Semin Immunol 2013;25:439-48
  15. Hausmann JS. Targeting cytokines to treat autoinflammatory disea